| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 7587.0 | 6864.5 | 6527.9 |
| Other income | 134.2 | 111.4 | 80.6 |
| Total income | 7721.2 | 6975.9 | 6608.5 |
| Profit before exceptional items & tax | 2057.2 | 1438.3 | 1891.6 |
| Exceptional items | 397.5 | 84.9 | 219.6 |
| Profit before tax | 1659.7 | 1353.4 | 1672.0 |
| Net profit | 1272.5 | 1042.1 | 1170.9 |
| Operating margin | 21.5% | 19.4% | 25.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +8.70% |
|---|---|
| Net profit, quarter on quarter | +22.10% |
| Revenue, year on year | +16.20% |
BSE results filing, NSE: ZYDUSLIFE. Figures extracted from the filing.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,154.00
- Market cap
- ₹1,16,119 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 25.7×Sector 47.4×
- Promoter holding
- 75.01%+0.01% QoQ
- FII holding
- 6.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences Credit Rating
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
- Value
- ₹55.46 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences announced positive Phase II(b) clinical trial results for Saroglitazar Mg in MASH. The global study successfully met its primary endpoint of resolution of steatohepatitis.
- Execution
- 52 weeks
Zydus Lifesciences Merger & Restructuring Worth ₹5 Cr
Zydus Lifesciences Limited has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in GIFT City, Gujarat. The subsidiary has a paid-up capital of Rs. 5 Crore.
- Value
- ₹5.00 Cr
Zydus Lifesciences Promoter Buying (Off-Market)
Zydus Lifesciences announced the transmission of 32,577 equity shares from Late Jasodaben Babubhai Patel to Mr. Prashant Babubhai Patel, both within the Promoter Group.